Implementing AHRQ Effective Health Care Reviews

Helping Clinicians Make Better Treatment Choices

Management of Insomnia Disorder in Adults

 

Am Fam Physician. 2018 Sep 1;98(5):319-322.

Related Practice Guideline: Treatment of Chronic Insomnia in Adults: ACP Guideline.

Author disclosure: No relevant financial affiliations.

Key Clinical Issue

What are the effectiveness, comparative effectiveness, and adverse effects of interventions for insomnia disorder in adults?

Evidence-Based Answer

Cognitive behavior therapy (CBT) for insomnia improves sleep outcomes in the general adult population. (Strength of Recommendation [SOR]: A, based on consistent, good-quality patient-oriented evidence.) The effectiveness of CBT for insomnia was consistent across different delivery modes (i.e., in person as an individual or with a group, by telephone, through the web, or using a self-help book) and was sustained in the long term, which was defined as at least six months. (SOR: B, based on inconsistent or limited-quality patient-oriented evidence.) There was insufficient evidence to report on the adverse effects of CBT for insomnia. Of the U.S. Food and Drug Administration–approved prescription drugs for insomnia, eszopiclone, zolpidem, and suvorexant improved some outcomes among the general adult population in primarily short-term studies of three months or less. (SOR: A, based on consistent, good-quality patient-oriented evidence.) There was limited evidence for the long-term safety of pharmacotherapy for insomnia (eTable A), although observational studies suggest possible associations with head injuries, cancer, and dementia. Data were insufficient to evaluate the effectiveness of benzodiazepines or over-the-counter sleep aids such as diphenhydramine, doxylamine, or melatonin.1

 Enlarge     Print

CLINICAL BOTTOM LINE

Effectiveness of Psychological and Behavioral Interventions for Insomnia Disorder When Compared with a Control*

InterventionGeneral adult populationAdults 55 years and olderAdults with pain conditions

Global outcomesSleep outcomesGlobal outcomesSleep outcomesGlobal outcomesSleep outcomes

Cognitive behavior therapy for insomnia†

Improves ● ○ ○ to ● ● ○

Improves ● ● ○

May improve ● ○ ○

Reduces awake time after sleep onset ● ● ○

May improve ● ○ ○

May improve some outcomes ● ○ ○

May improve other outcomes ● ○ ○

Cognitive behavior therapy for insomnia (studies lasting ≥ six months)

May improve ● ○ ○

Improves sleep efficiency ● ● ○

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

May improve other outcomes ● ○ ○

Stimulus control‡

○ ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

May improve total sleep time ● ○ ○

○ ○ ○

○ ○ ○

Multicomponent behavior therapy or brief behavior therapy

○ ○ ○

○ ○ ○

○ ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

○ ○ ○


Strength of evidence scale

● ● ● High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change the confidence in the estimate of effect.

● ● ○ Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change the confidence in the estimate of effect and may change the estimate.

● ○ ○ Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.

○ ○ ○ Insufficient: Evidence either is unavailable or does not permit a conclusion.

*—Controls included treatment as usual, attention control (i.e., sleep hygiene, sleep education), wait-list management, placebo or sham treatment, or no treatment.

†—The effectiveness of cognitive behavior therapy for insomnia was demonstrated across modes of delivery: in person as an individual, in person as a group, telephone, web-based, and self-help book.

‡—These results refer to stimulus control alone. Stimulus control is also often a component of cognitive behavior therapy for insomnia, multicomponent behavior, and brief behavior therapy.

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

CLINICAL BOTTOM LINE

Effectiveness of Psychological and Behavioral Interventions for Insomnia Disorder When Compared with a Control*

InterventionGeneral adult populationAdults 55 years and olderAdults with pain conditions

Global outcomesSleep outcomesGlobal outcomesSleep outcomesGlobal outcomesSleep outcomes

Cognitive behavior therapy for insomnia†

Improves ● ○ ○ to ● ● ○

Improves ● ● ○

May improve ● ○ ○

Reduces awake time after sleep onset ● ● ○

May improve ● ○ ○

May improve some outcomes ● ○ ○

May improve other outcomes ● ○ ○

Cognitive behavior therapy for insomnia (studies lasting ≥ six months)

May improve ● ○ ○

Improves sleep efficiency ● ● ○

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

May improve other outcomes ● ○ ○

Stimulus control‡

○ ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

May improve total sleep time ● ○ ○

○ ○ ○

○ ○ ○

Multicomponent behavior therapy or brief behavior therapy

○ ○ ○

○ ○ ○

○ ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

○ ○ ○


Strength of evidence scale

● ● ● High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change the confidence in the estimate of effect.

● ● ○ Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change the confidence in the estimate of effect and may change the estimate.

● ○ ○ Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.

○ ○ ○ Insufficient: Evidence either is unavailable or does not permit a conclusion.

*—Controls included treatment as usual, attention control (i.e., sleep hygiene, sleep education), wait-list management, placebo or sham treatment, or no treatment.

†—The effectiveness of cognitive behavior therapy for insomnia was demonstrated across modes of delivery: in person as an individual, in person as a group, telephone, web-based, and self-help book.

‡—These results refer to stimulus control alone. Stimulus control is also often a component of cognitive behavior therapy for insomnia, multicomponent behavior, and brief behavior therapy.

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

 Enlarge     Print

CLINICAL BOTTOM LINE

Effectiveness of Pharmacologic Interventions for Insomnia Disorder When Compared with Placebo

DrugGeneral adult populationAdults 55 years and older

Global outcomesSleep outcomes*Global outcomesSleep outcomes*

Nonbenzodiazepine hypnotics

Eszopiclone

May improve ● ○ ○

Improves sleep onset latency and total sleep time ● ● ○

May improve ● ○ ○

May improve some outcomes ● ○ ○

May reduce time awake after sleep onset ● ○ ○

Zolpidem†

May improve ● ○ ○

Improves sleep onset latency, total sleep time, and sleep quality ● ● ○

○ ○ ○

May improve sleep onset latency ● ○ ○

May reduce time awake after sleep onset ● ○ ○

Zolpidem, extended release

May improve ● ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

○ ○ ○

Zaleplon

○ ○ ○

Improves sleep quality ● ● ○

○ ○ ○

○ ○ ○

Probably has no effect on total sleep time ● ○ ○

Orexin receptor antagonists

Suvorexant

Improves ● ● ○

Improves sleep onset latency and total sleep time ● ● ○

○ ○ ○

○ ○ ○

Reduces time awake after sleep onset ● ● ○

Melatonin agonists

Ramelteon

○ ○ ○

May improve sleep quality ● ○ ○

○ ○ ○

May improve sleep onset latency ● ○ ○

Probably has no effect on other outcomes ● ○ ○

Antidepressants

Doxepin

○ ○ ○

May improve some outcomes ● ○ ○

May improve ● ○ ○

Improves totalsleep time ● ● ○ May improve other outcomes ● ○ ○

Others‡

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Benzodiazepines

Temazepam

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Others§

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Over-the-counter sleep medications and supplements

Diphenhydramine, doxylamine, melatonin

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○


Strength of evidence scale

● ● ● High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change the confidence in the estimate of effect.

● ● ○ Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change the confidence in the estimate of effect and may change the estimate.

● ○ ○ Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.

○ ○ ○ Insufficient: Evidence either is unavailable or does not permit a conclusion.

Note: Most studies of pharmacologic interventions were small and of short duration (less than three months).

FDA = U.S. Food and Drug Administration.

*—Sleep outcomes include sleep onset latency, total sleep time, time awake after sleep onset, sleep efficiency, and sleep quality.

†—Data are from studies of the routine use of zolpidem, 10 mg or 15 mg, or as-needed use of zolpidem, 10 mg, for the general adult population and zolpidem, 5 mg, for the older adult population.

‡—Other antidepressants include trazodone, amitriptyline, and mirtazapine, none of which are approved by the FDA for insomnia.

§—Other benzodiazepines include drugs approved by the FDA for insomnia (estazolam, flurazepam, lorazepam, quazepam, triazolam) and drugs not approved by the FDA for insomnia (alprazolam, clonazepam).

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

CLINICAL BOTTOM LINE

Effectiveness of Pharmacologic Interventions for Insomnia Disorder When Compared with Placebo

DrugGeneral adult populationAdults 55 years and older

Global outcomesSleep outcomes*Global outcomesSleep outcomes*

Nonbenzodiazepine hypnotics

Eszopiclone

May improve ● ○ ○

Improves sleep onset latency and total sleep time ● ● ○

May improve ● ○ ○

May improve some outcomes ● ○ ○

May reduce time awake after sleep onset ● ○ ○

Zolpidem†

May improve ● ○ ○

Improves sleep onset latency, total sleep time, and sleep quality ● ● ○

○ ○ ○

May improve sleep onset latency ● ○ ○

May reduce time awake after sleep onset ● ○ ○

Zolpidem, extended release

May improve ● ○ ○

May improve some outcomes ● ○ ○

○ ○ ○

○ ○ ○

Zaleplon

○ ○ ○

Improves sleep quality ● ● ○

○ ○ ○

○ ○ ○

Probably has no effect on total sleep time ● ○ ○

Orexin receptor antagonists

Suvorexant

Improves ● ● ○

Improves sleep onset latency and total sleep time ● ● ○

○ ○ ○

○ ○ ○

Reduces time awake after sleep onset ● ● ○

Melatonin agonists

Ramelteon

○ ○ ○

May improve sleep quality ● ○ ○

○ ○ ○

May improve sleep onset latency ● ○ ○

Probably has no effect on other outcomes ● ○ ○

Antidepressants

Doxepin

○ ○ ○

May improve some outcomes ● ○ ○

May improve ● ○ ○

Improves totalsleep time ● ● ○ May improve other outcomes ● ○ ○

Others‡

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Benzodiazepines

Temazepam

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Others§

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○

Over-the-counter sleep medications and supplements

Diphenhydramine, doxylamine, melatonin

○ ○ ○

○ ○ ○

○ ○ ○

○ ○ ○


Strength of evidence scale

● ● ● High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change the confidence in the estimate of effect.

● ● ○ Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change the confidence in the estimate of effect and may change the estimate.

● ○ ○ Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.

○ ○ ○ Insufficient: Evidence either is unavailable or does not permit a conclusion.

Note: Most studies of pharmacologic interventions were small and of short duration (less than three months).

FDA = U.S. Food and Drug Administration.

*—Sleep outcomes include sleep onset latency, total sleep time, time awake after sleep onset, sleep efficiency, and sleep quality.

†—Data are from studies of the routine use of zolpidem, 10 mg or 15 mg, or as-needed use of zolpidem, 10 mg, for the general adult population and zolpidem, 5 mg, for the older adult population.

‡—Other antidepressants include trazodone, amitriptyline, and mirtazapine, none of which are approved by the FDA for insomnia.

§—Other benzodiazepines include drugs approved by the FDA for insomnia (estazolam, flurazepam, lorazepam, quazepam, triazolam) and drugs not approved by the FDA for insomnia (alprazolam, clonazepam).

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

 Enlarge     Print

eTABLE A

Adverse Effects of Pharmacologic Interventions for Insomnia Disorder: Systematic Review Findings and FDA Label Information

Drug classDrugCommon effects*Serious effects

Nonbenzodiazepine hypnotics

Eszopiclone

Somnolence, unpleasant taste in the mouth, headache, dizziness, dry mouth, rash, anxiety, hallucinations, respiratory infection

Central nervous system depressant effects and next-day psychomotor impairment Increased central nervous system effects in older adults Sleep-driving and other complex behaviors while not fully awake Worsening depression or suicidal thoughts Falls and severe injuries because of drowsiness Severe anaphylactic or anaphylactoid reactions Possible respiratory depression in persons with severe lung disease or sleep apnea Withdrawal symptoms if abrupt dose reduction or discontinuation

Zolpidem

Somnolence, headache, malaise, vertigo, dizziness, diarrhea

Zaleplon

Headache, drowsiness, dizziness, paresthesias, difficulty with coordination

Benzodiazepines

Temazepam

Drowsiness, dizziness, headache, nervousness, nausea

Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Worsening depression or suicidal thoughts in persons with primary depression Severe anaphylactic or anaphylactoid reactions Possible profound sedation, respiratory depression, coma, and death with concomitant opioid use Possible adverse effects in persons with severe lung disease or sleep apnea

Orexin receptor antagonists

Suvorexant

Somnolence, fatigue, dry mouth

Central nervous system depressant effects and next-day psychomotor impairment Sleep-driving and other complex behaviors while not fully awake Sleep paralysis, hypnagogic or hypnopompic hallucinations, cataplexy-like symptoms Worsening depression or suicidal thoughts Possible respiratory depression in persons with severe lung disease or sleep apnea

Melatonin agonists

Ramelteon

Somnolence, fatigue, headache, dizziness, worsened insomnia, nausea

Potential impairment of activities requiring complete mental alertness after drug ingestion Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Worsening depression or suicidal thoughts Severe anaphylactic or anaphylactoid reactions Decreased testosterone and increased prolactin levels Possible adverse effects in persons with severe sleep apnea

Antidepressants

Doxepin

Drowsiness, nausea, upper respiratory tract infection

Central nervous system depressant effects, with impaired alertness and motor coordination that may persist the next day Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Potential addictive effects when combined with central nervous system depressants or sedating antihistamines Worsening depression or suicidal thoughts Possible respiratory depression in persons with severe lung disease or sleep apnea


FDA = U.S. Food and Drug Administration.

*—Adverse effects reported in randomized controlled trials and observational studies in the systematic review, as well as common adverse effects listed in the FDA labels for each drug.

†—Adverse effects accompanied by warnings or precautions statements in the FDA labels.

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effective-healthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

eTABLE A

Adverse Effects of Pharmacologic Interventions for Insomnia Disorder: Systematic Review Findings and FDA Label Information

Drug classDrugCommon effects*Serious effects

Nonbenzodiazepine hypnotics

Eszopiclone

Somnolence, unpleasant taste in the mouth, headache, dizziness, dry mouth, rash, anxiety, hallucinations, respiratory infection

Central nervous system depressant effects and next-day psychomotor impairment Increased central nervous system effects in older adults Sleep-driving and other complex behaviors while not fully awake Worsening depression or suicidal thoughts Falls and severe injuries because of drowsiness Severe anaphylactic or anaphylactoid reactions Possible respiratory depression in persons with severe lung disease or sleep apnea Withdrawal symptoms if abrupt dose reduction or discontinuation

Zolpidem

Somnolence, headache, malaise, vertigo, dizziness, diarrhea

Zaleplon

Headache, drowsiness, dizziness, paresthesias, difficulty with coordination

Benzodiazepines

Temazepam

Drowsiness, dizziness, headache, nervousness, nausea

Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Worsening depression or suicidal thoughts in persons with primary depression Severe anaphylactic or anaphylactoid reactions Possible profound sedation, respiratory depression, coma, and death with concomitant opioid use Possible adverse effects in persons with severe lung disease or sleep apnea

Orexin receptor antagonists

Suvorexant

Somnolence, fatigue, dry mouth

Central nervous system depressant effects and next-day psychomotor impairment Sleep-driving and other complex behaviors while not fully awake Sleep paralysis, hypnagogic or hypnopompic hallucinations, cataplexy-like symptoms Worsening depression or suicidal thoughts Possible respiratory depression in persons with severe lung disease or sleep apnea

Melatonin agonists

Ramelteon

Somnolence, fatigue, headache, dizziness, worsened insomnia, nausea

Potential impairment of activities requiring complete mental alertness after drug ingestion Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Worsening depression or suicidal thoughts Severe anaphylactic or anaphylactoid reactions Decreased testosterone and increased prolactin levels Possible adverse effects in persons with severe sleep apnea

Antidepressants

Doxepin

Drowsiness, nausea, upper respiratory tract infection

Central nervous system depressant effects, with impaired alertness and motor coordination that may persist the next day Abnormal thinking, behavior changes, complex behaviors (including sleep-driving, hallucinations) Potential addictive effects when combined with central nervous system depressants or sedating antihistamines Worsening depression or suicidal thoughts Possible respiratory depression in persons with severe lung disease or sleep apnea


FDA = U.S. Food and Drug Administration.

*—Adverse effects reported in randomized controlled trials and observational studies in the systematic review, as well as common adverse effects listed in the FDA labels for each drug.

†—Adverse effects accompanied by warnings or precautions statements in the FDA labels.

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Quality; August 2017. https://effective-healthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15, 2018.

Practice Pointers

Insomnia is a common problem addressed by family physicians and accounts for more than 5.5 million outpatient visits annually.2 The Diagnostic and Statistical Manual of Mental Disorders, 5th ed., defines insomnia disorder as recurrent poor sleep quality or quantity that causes distress or dysfunction and lasts for longer than three months.3 Insomnia is associated with older age; female sex; mental illness; poor general health; lower socioeconomic status; and decreased memory, mood, and cognitive function.4 Persons with sleep problems report higher levels of depressed mood, anxiety, physical pain and discomfort, and cognitive deficiencies.5

This Agency for Healthcare Research and Quality (AHRQ) review included 59 randomized controlled trials studying psychological interventions in the general adult population, older adults, and adults with pain conditions. Results included global outcomes, such as improvements in sleep and daytime dysfunction or distress, and sleep outcomes, which assessed specific sleep parameters (sleep onset latency, time awake after sleep onset, total sleep time, sleep quality, and sleep efficiency). Duration of insomnia ranged from six months to 19 years, with a duration of more than 10 years in most studies.

Psychological interventions included stimulus control, sleep restriction, relaxation techniques, sleep hygiene education, and CBT for insomnia. CBT for insomnia is a combination of cognitive therapy, behavioral interventions (i.e., sleep restriction and stimulus control), and education (i.e., sleep hygiene). There were insufficient data to draw conclusions on the effectiveness of specific interventions alone (e.g., stimulus control, sleep restriction, relaxation techniques), but based on a meta-analysis of 20 trials, CBT for insomnia improved global and sleep outcomes in the general adult population. Improvements were sustained for at least six months. Among older adults and patients with pain conditions, CBT for insomnia improved global outcomes and some sleep outcomes. There was insufficient evidence to assess adverse effects of psychological treatments.

There were 38 randomized controlled trials identified that evaluated pharmacologic therapies, including nonbenzodiazepine hypnotics (eszopiclone, zaleplon, zolpidem), an orexin receptor antagonist (suvorexant), melatonin agonists (prolonged-release melatonin, ramelteon), an antidepressant (doxepin), and a benzodiazepine hypnotic (temazepam). Most of these studies were of short duration and had a small sample size. Eszopiclone, zolpidem, and suvorexant had the strongest evidence of effectiveness in the general adult population for global and sleep outcomes. Doxepin had the strongest evidence of effectiveness for global and sleep outcomes among adults 55 years and older. Ramelteon did not improve global or sleep outcomes in a clinically meaningful way when compared with placebo. Very few benzodiazepine trials met eligibility criteria primarily because of short treatment duration, and data from the included studies were insufficient to assess sleep outcomes. Adverse events were mixed across studies, with few differences compared with placebo.

Psychological and behavioral interventions are considered first-line treatments for insomnia. Consistent with findings from this AHRQ study, guidelines from the American College of Physicians and the American Academy of Sleep Medicine recommend CBT as the first-line treatment for all adults with chronic insomnia disorder.68 When CBT for insomnia is not effective or does not achieve desired results, the American College of Physicians recommends using shared decision making when considering short-term medication therapy for chronic insomnia. The U.S. Food and Drug Administration has approved pharmacologic therapy for short-term use (four to five weeks) and suggests that medications not be used for extended periods. If insomnia does not improve after seven to 10 days of pharmacotherapy, the patient should be further evaluated.8

Editor's Note: American Family Physician SOR ratings are different from the AHRQ Strength of Evidence (SOE) ratings.

The associated AHRQ product was funded under Contract No. HHSA 290-2012-00016-I Task Order 12 from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS). The authors of this manuscript are responsible for its content. Statements in the manuscript do not necessarily represent the official views of or imply endorsement by AHRQ or HHS.

Author disclosure: No relevant financial affiliations.

Address correspondence to Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FASAM, FACPM, at elizabeth.salisbury@gmail.com. Reprints are not available from the author.

References

show all references

1. Agency for Healthcare Research and Quality, Effective Health Care Program. Management of insomnia disorder in adults: current state of the evidence. Clinician research summary. Rockville, Md.: Agency for Healthcare Research and Qualit y; August 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf. Accessed May 15...

2. Ford ES, Wheaton AG, Cunningham TJ, Giles WH, Chapman DP, Croft JB. Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999–2010. Sleep. 2014;37(8):1283–1293.

3. Sleep-wake disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

4. Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and management of chronic insomnia in adults. Evid Rep Technol Assess (Summ). 2005;125:1–10.

5. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010;14(1):69–82.

6. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.

7. Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133.

8. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep. 2006;29(11):1415–1419.

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to produce evidence to improve health care and to make sure the evidence is understood and used. A key clinical question based on the AHRQ Effective Health Care Program systematic review of the literature is presented, followed by an evidence-based answer based upon the review. AHRQ's summary is accompanied by an interpretation by an AFP author that will help guide clinicians in making treatment decisions.

See the full review, clinician summary, and consumer summary.

This series is coordinated by Kenny Lin, MD, MPH, Deputy Editor.

A collection of Implementing AHRQ Effective Health Care Reviews published in AFP is available at https://www.aafp.org/afp/ahrq.

 

 

Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2019

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article